logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Accepts Impax Pharma NDA Filing For IPX066 - Quick Facts

Impax Laboratories, Inc.'s (IPXL) branded products division, Impax Pharmaceuticals, said the U.S. Food and Drug Administration has accepted for filing the company's New Drug Application, or NDA, for IPX066 for the treatment of idiopathic Parkinson's disease submitted to the Agency on December 21, 2011. The Prescription Drug User Fee Date for a decision by the FDA is October 21, 2012.

IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.

The NDA included data from three controlled Phase III studies and two open label extensions of IPX066 in both early and advanced Parkinson's disease.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Netflix Inc. (NFLX), Monday gained over 8 percent in extended trading session after the online-video streaming service reported a fourth-quarter profit that trumped analysts estimates, driven largely by higher-than-expected subscriber additions both domestically and internationally. Netflix... American Airlines (AAL) Wednesday announced that it has launched a new Basic Economy fares. The basic economy fares will go on sale in February in 10 markets, with the fares to be expanded to other additional markets later this year. However, not every American Airlines flight will offer basic economy... Chuck E. Cheese pizza and arcade chain's parent company is planning for an IPO, reported Reuters. The public offering would be probably in the second half of 2017. According to the report, the chain has initiated discussions with banks, however has not yet hired any underwriters. The offering would help the restaurant chain for a valuation of around $1 billion.
comments powered by Disqus
Follow RTT